Translational Stroke Program, Neuroscience Institute, Morehouse School of Medicine, 720 Westview Dr SW, Atlanta, GA, 30310, USA.
Exscien Corp, Mobile, AL, 36688, USA.
Transl Stroke Res. 2019 Dec;10(6):664-671. doi: 10.1007/s12975-018-0680-5. Epub 2018 Dec 8.
We hypothesize that enhancing mitochondrial base excision repair (BER) capability in brain will reduce reperfusion-associated ischemic brain injury. Post-stroke reperfusion was modeled in mice via transient filament occlusion of the middle cerebral artery (60 min) (transient MCAO). Administration of a TAT-modified form of a DNA glycosylase (EndoIII) following reperfusion of the brain reduced resultant brain infarct volume. Protection was dose-dependent, BER enzyme specific, and regionally specific (more effective via the jugular vein). EndoIII is compatible with tissue plasminogen activator (tPA). The time window of a single dose of EndoIII effect is 3 h following reperfusion onset. These data suggest a novel approach to enhance protection of reperfused brain in the setting of revascularization procedures (thrombectomy or thrombolytic therapy) following stroke.
我们假设增强大脑中线粒体碱基切除修复(BER)能力将减少再灌注相关的缺血性脑损伤。通过短暂性大脑中动脉闭塞(60 分钟)(短暂性 MCAO)在小鼠中模拟卒中后再灌注。在脑再灌注后给予 TAT 修饰的 DNA 糖苷酶(EndoIII)可减少脑梗死体积。保护作用呈剂量依赖性、BER 酶特异性和区域性特异性(通过颈静脉更有效)。EndoIII 与组织型纤溶酶原激活物(tPA)兼容。单次给予 EndoIII 的作用时间窗口是再灌注开始后 3 小时。这些数据表明,在血管再通程序(血栓切除术或溶栓治疗)后,针对再灌注脑有一个增强保护的新方法。